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Background: Approximately 7% of survivors from meningococcal meningitis (MM) suffer from neurological
sequelae due to brain damage in the course of meningitis. The present study focuses on the role of matrix
metalloproteinases (MMPs) in a novel mouse model of MM-induced brain damage.
Methods: The model is based on intracisternal infection of BALB/c mice with a serogroup C Neisseria meningitidis
strain. Mice were infected with meningococci and randomised for treatment with the MMP inhibitor batimastat
(BB-94) or vehicle. Animal survival, brain injury and host-response biomarkers were assessed 48 h after meningococcal
challenge.
Results: Mice that received BB-94 presented significantly diminished MMP-9 levels (p < 0.01), intracerebral bleeding
(p < 0.01), and blood-brain barrier (BBB) breakdown (p < 0.05) in comparison with untreated animals. In mice suffering
from MM, the amount of MMP-9 measured by zymography significantly correlated with both intracerebral haemorrhage
(p < 0.01) and BBB disruption (p < 0.05).
Conclusions: MMPs significantly contribute to brain damage associated with experimental MM. Inhibition of MMPs
reduces intracranial complications in mice suffering from MM, representing a potential adjuvant strategy in MM
post-infection sequelae.
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Neisseria meningitidis is an obligate human pathogen that
colonises the nasopharyngeal mucosa of 10-30% individ-
uals, with carriage rates increasing with age from small
children to young adults. In a minor proportion of carriers,
asymptomatic colonisation may progress into invasive
meningococcal disease. The clinical manifestations of
meningococcal disease (MD) vary considerably, ranging
from transient bacteremia to meningitis and/or fulminant* Correspondence: susanna.ricci@unisi.it
†Equal contributors
1Department of Medical Biotechnologies, Laboratory of Molecular
Microbiology and Biotechnology (LA.M.M.B.), Ospedale Santa Maria alle
Scotte (V lotto, piano 1), University of Siena, Viale Bracci, 53100 Siena, Italy
6The ESCMID Study Group for Infectious Diseases of the Brain (ESGIB), Basel,
Switzerland
Full list of author information is available at the end of the article
© 2014 Ricci et al.; licensee BioMed Central. Th
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.sepsis [1,2]. The most common clinical presentation of
MD is meningococcal meningitis (MM), which can affect
30-60% of infected patients, with adolescents and young
adults being the age group at higher risk [3,4]. MM is asso-
ciated with 5-16% mortality [3]. Approximately 7% of MM
survivors suffer from long-term neurological sequelae (i.e.,
hearing loss, cognitive impairment, motor deficits, sei-
zures) due to brain damage in the course of meningitis [5].
Both the host immune response to the pathogen and
the direct cytotoxicity of bacterial components are re-
sponsible for brain tissue damage [6,7]. Polymorpho-
nuclear cells (PMNs), macrophages and microglia that
are recruited to the damaged tissue release reactive oxy-
gen species, matrix metalloproteinases (MMPs), cyto-
kines and excitatory amino acids, finally leading to
energy failure and cell death [6,7].is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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role in inflammation, innate immunity and tissue turnover.
Not only do they target extracellular matrix proteins, but
act as sheddases on non-matrix proteins, such as cyto- and
chemokines (and their receptors) and antimicrobial pep-
tides [8]. A pathogenic role for MMPs has been suggested
for various diseases, including arthritis, cancer, multiple
sclerosis, stroke and bacterial meningitis (BM) [9,10]. MMP
levels are increased in the cerebrospinal fluid (CSF) of both
adults and children with BM [11-13], and high concentra-
tions of the gelatinase MMP-9 are considered a risk factor
for the development of neurological sequelae [12]. Several
experimental models of pneumococcal meningitis (PM)
have demonstrated that MMPs contribute to brain damage
by participating in blood-brain barrier (BBB) breakdown,
PMN recruitment, shedding of cytokines as well as their re-
ceptors, and cortical damage [14-16]. Therapy with MMP
inhibitors in experimental PM significantly improved ani-
mal mortality, neuronal injury, hearing loss, seizures and
learning abilities [17-21]. In contrast to plentiful data on
MMPs in PM models, the importance of MMPs in experi-
mental MM has hardly been reported [11,22], due to the
recognised difficulties of mimicking MD/MM in animal
models.
Humans are the only natural hosts for N. meningitidis
due to the species-specificity of iron meningococcal up-
take systems and surface structures. Current animal
models of MD consist in mice or rats infected either via
the intraperitoneal or intranasal route. In order to compel
meningococcal replication in the rodent host, several
strategies were attempted, including the use of high bac-
terial inocula, neonatal or immunocompromised animals,
animal passage prior to infection, or administration of an
exogenous source of iron [23-27]. Transgenic mice for
human CD46 [28] or transferrin [29] have also been
employed to overcome shortcomings of traditional sys-
tems. Recently, an MM mouse model based on intracister-
nal infection of adult mice with group C N. meningitidis
has been developed [30]. Meningococci efficiently multi-
plied in the brain and induced meningitis with features
mimicking those present in humans [30].
In this study, we have developed a novel mouse model
of MM-induced brain damage and demonstrated the
therapeutic efficacy of batimastat, a broad MMP inhibitor,
in experimental MM. Evaluation of cerebral haemorrhage,
BBB breakdown and apoptosis in the hippocampus
showed reduced intracranial complications in mice treated
with batimastat, suggesting a key role for MMPs in brain
damage associated with MM.
Methods
N. meningitidis
The serogroup C 93/4286 isolate, belonging to the ET-
37 hypervirulent lineage, was cultured on chocolate GCagar media (Oxoid, Milano, Italy) or CG broth (Oxoid)
supplemented with 1% (v/v) Vitox (Oxoid) at 37°C in 5%
CO2. Inocula for mouse challenge were prepared by cul-
tivating bacteria in GC broth until mid-logarithmic
phase. Viable counts were performed, and bacteria were
frozen at -80°C with 10% glycerol until use.
Mice
Six-weeks-old female BALB/c mice were obtained from
Charles River (Calco, Italy). Animal experiments were
authorised by the local ethics committee (Comitato Etico
Locale, Azienda Ospedaliera Universitaria Senese,
21.05.2012) and the Italian Ministry of Health (docu-
ment no. 131/2013, 30.05.2013), and were carried out
according to institutional guidelines.
Model of MM-induced brain damage
The model of brain damage was developed based on a
previously reported MM model in the mouse [30]. Bac-
teria were thawed, centrifuged for 5 min at 1800 x g, and
suspended in GC broth with iron dextran (5 mg/kg;
Sigma-Aldrich, Milano, Italy) at a final concentration of
108 cfu/ml. Approximately 2 h prior to infection, ani-
mals were injected intraperitoneally (i.p.) with iron dex-
tran (250 mg/kg). Mice were lightly anaesthetised by i.p.
injection with Zoletil 20 [(tiletamine and zolazepam
hydrochloride), 15 mg/kg; Virbac Srl, Milano, Italy] and
Xilor [(xylazine 2%), 4 mg/kg; Bio 98 Srl, Milano, Italy]
and infected by the intracisternal (i.c.) route with 10 μl
of the bacterial inoculum (106 cfu/mouse corresponding
to a lethal dose killing 20% of animals, LD20). Mice were
monitored for clinical signs according to a previously de-
scribed coma scale [21] and euthanised if/when they
reached a score of 2. Briefly, coma scale was as follows:
1 = coma, 2 = does not stand upright, 3 = stands upright
within 30 sec, 4 = stands upright within 5 sec, minimal
ambulatory activities, 5 = normal.
Treatment with BB-94
Mice were treated i.p. with batimastat (BB-94; 50 mg/kg)
1 h before and 24 h post-infection. BB-94 (Merck Che-
micals Ltd., Nottingham, United Kingdom) was sus-
pended at 50 mg/ml in dimethylsulfoxide (DMSO) and
stored frozen at -20°C. Prior to use, it was diluted 20-
fold in phosphate buffered saline (PBS), and 500 μl were
injected into animals. Control mice were injected with
500 μl of 5% DMSO in PBS. Animals were sacrificed
48 h after i.c. challenge.
Experimental design and sample collection
Three independent experiments were performed with a
total number of 41 mice (control, n = 20; treated, n = 21).
Upon sacrifice, mice were deeply anaesthetised by i.p. in-
jection with Zoletil 20 (30 mg/kg; Virbac Srl) and Xilor
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cold PBS. Brains were removed and dissected into the two
hemispheres and cerebellum. One hemisphere was fixed
in 4% paraformaldehyde (PFA) in PBS (w/v) for histo-
logical analysis, while the other one was frozen in dry ice
for assessment of intracerebral bleeding and BBB break-
down. Cerebella were frozen in dry ice for MMP and cyto-
kine analysis. Samples were not collected from animals
unsuccessfully perfused, found dead or humanely sacri-
ficed before 48 h. Thus, analyses were conducted on a
total of 13 control and 20 BB-94-treated mice.Brain histomorphometry
Cortical necrosis and apoptosis in the dentate gyrus of
hippocampus were assessed as previously described [21].
Hemispheres were prepared for cryopreservation by in-
cubation in 18% sucrose in PBS (w/v) at 4°C overnight.
Forty-five μm-thick coronal sections obtained by ran-
dom uniform sampling were stained with cresyl violet
for Nissl substance. Histological features of apoptosis
(condensed and/or fragmented dark nuclei, apoptotic
bodies) were counted in 4 different slices spanning the
hippocampus. Three visual fields in the two blades of
the dentate gyrus were inspected. The number of apop-
totic cells/visual field (apoptotic score) was determined,
and a mean apoptotic score was calculated for each ani-
mal. Cortical damage was defined as areas of decreased
neuronal density or frank cortical necrosis and evaluated
on digitised brain section images using the ImageJ ana-
lysis software (U.S. National Institutes of Health, Be-
thesda, Maryland, USA) [31]. The volume of cortical
damage was assessed in at least 16 brain sections/mouse
and expressed as a percentage of the total cortical vol-
ume according to the Cavalieri principle as already de-
scribed [32].Quantification of cyto-/chemokines and MMP-9
Cyto-/chemokines and MMP-9 in cerebella homoge-
nates were quantified by using microsphere-based multi-
plex assays (Milliplex MAP mouse cytokine/chemokine
multiplex assay and Milliplex MAP mouse CVD panel 1
multiplex assay, Merck Millipore, Billerica, MA, USA).
Cerebella were homogenised with a glass Dounce hom-
ogeniser in 1:7 (w/v) extraction buffer containing 0.1%
Triton X-100 and a protease inhibitor cocktail (Roche
Diagnostics, Rotkreuz, Switzerland) in PBS. One hun-
dred μg (for cyto-/chemokines) or 1 μg (for MMP-9) of
homogenates were tested in duplicate. A minimum of 50
beads per analyte was measured using a Bio-Plex 200
station (Bio-Rad Laboratories, Hercules, CA, USA). Cali-
bration curves from recombinant standards were calcu-
lated with the Bio-Plex Manager software version 4.1.1
using a five-parameter logistic curve fitting.Gelatin-sepharose affinity binding
Homogenised cerebella were centrifuged at 16000 x g
for 10 min at 4°C, and the protein content was deter-
mined by the BCA protein assay (Pierce, Thermo Fischer
Scientific, Reinach, Switzerland). Gelatinases were
enriched by incubating 100 μg of homogenates with
20 μl of Gelatin Sepharose 4B (GE Healthcare GmbH,
Glattbrugg, Switzerland) on an orbital shaker overnight
at 4°C. Sepharose beads were washed (50 mM Tris-HCl
pH 7.6, 150 mM NaCl, 5 mM CaCl2, 0.02% NaN3, 0.05%
Brij 25, 1% Triton X-100) and then incubated with 2X
zymography sample buffer (30 mM Tris HCl pH 6.8,
20% glycerol, 1% sodium dodecyl sulphate (SDS), 0.02%
bromophenol blue) for 5 min at room temperature to
elute bound proteins. After centrifugation, supernatants
were collected and tested by gelatin gel zymography.
Gelatin zymography
Gelatin zymography was performed as described [21].
Samples were subjected to electrophoresis under non-
reducing conditions in polyacrylamide gels containing
1% (v/v) type A gelatin from porcine skin (Sigma-Al-
drich). After electrophoresis, SDS was removed from the
gels, and the MMP catalytic sites were activated by over-
night incubation at 37°C in zymography buffer (10 mM
CaCl2, 50 mM Tris, 50 mM NaCl, pH 7.65). Gels were
stained with 0.1% Coomassie Brilliant Blue R250 (Sigma-
Aldrich), 30% methanol and 10% acetic acid. Gelatinoly-
tic activity was determined by densitometric quantifica-
tion of the substrate lysis zones around 92 (pro-MMP-9)
and 72 (pro-MMP-2) kDa using the ImageJ analysis soft-
ware [31]. Purified human neutrophil MMP-9 and
MMP-2 (Calbiochem, Darmstadt, Germany) were used
as standards for normalisation and quantification of
MMP-9 and MMP-2 as a function of the lysis zone. A
strong correlation was calculated between MMP-9 quan-
tification obtained by gel zymography and by the Milli-
plex assay (Pearson’s test, ρ = 0.83, p < 0.0001).
Analysis of cerebral bleeding
Cerebral haemorrhages were assessed as previously de-
scribed [33]. Briefly, brain hemispheres were cut in a
frontal plane into 30 μm-thick sections, and serial sections
were photographed with a digital camera at 0.3 mm-inter-
vals. For each animal, 5 comparable brain sections were
analysed. The bleeding spots were counted, and the rela-
tive areas of bleeding were measured by using the
UTHSCSA Image Tool (Texas, USA). Cumulative bleed-
ing areas were divided by the whole slice area and com-
puted into a total bleeding area/whole slice area x 1000.
Assessment of BBB integrity
The integrity of BBB was estimated by quantifying
mouse serum albumin in brain homogenates by enzyme-
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ported [34]. In brief, brain slices were dissolved in lysis
buffer containing 0.1% NaN3 and homogenised in an
ultrasound bath for 20 sec. After centrifugation, superna-
tants were collected and subjected to the Roti®-Nanoquant
assay (Carl Roth GmbH+Co.KG, Karlsruhe, Germany) to
quantify the total protein content. For each sample, 0.5 μg
of total protein were subjected to albumin ELISA (Bethyl/
Biomol GmbH, Hamburg, Germany) according to the
manufacturer’s instructions.0 12 24 36 48
Time (h)
Figure 1 Effect of treatment with BB-94 on survival of mice
with MM. BALB/c mice were infected i.c. with 106 cfu/mouse of
strain 93/4286 (group C) of N. meningitidis, injected i.p. with either
BB-94 (n = 21) or vehicle (n = 20), and sacrificed 48 h later. Treatment
with BB-94 (50 mg/kg) was carried out 1 h before and 24 h post-
infection. Data are represented as a Kaplan-Meier survival curve.Statistical analyses
Results are presented as mean values ± standard deviation.
Mouse survival was estimated by the Kaplan-Meier sur-
vival analysis, and differences were compared using the
log-rank test (p < 0.05). Differences in MMP-9 gelatinoly-
tic activity, apoptosis, BBB integrity and cerebral bleeding
between mice treated with BB-94 and controls were evalu-
ated using the Mann-Whitney U test (p < 0.05). Correl-
ation was measured by the Pearson’s analysis (p < 0.05).Results
The impact of treatment with BB-94 on MM outcome in
infected mice was evaluated by assessing animal survival,
brain damage, and levels of MMPs and cyto-/chemo-
kines 48 h after meningococcal challenge. Upon sacri-
fice, the clinical scores of surviving mice were 3 (2-4)
[median (range)] irrespective of the group (p > 0.05).
Kaplan-Meier analysis of survival (at 48 h) showed that
animals treated with BB-94 had increased survival
(95.2%) in comparison with controls (75%), and differ-
ences were almost statistically significant (p = 0.064),
(Figure 1). The concentrations of interleukin (IL)-1β, IL-
10, monocyte chemoattractant protein 1 (MCP-1) and
macrophage inflammatory protein 1α (MIP-1α) were
slightly reduced in cerebella of treated animals, without
reaching statistical significance (data not shown).BB-94 reduces MMP-9 levels in the brain of mice with MM
To evaluate whether BB-94 diminished the levels of
MMPs in the brain, gelatin zymography was performed
on cerebella of treated and control animals after MM in-
duction. Densitometric analysis showed no relevant
changes in MMP-2 levels between samples from the two
mouse groups. In contrast, the amount of MMP-9 was
diminished in cerebella of mice that had received BB-94
compared to those injected with vehicle (Figure 2A).
Quantitative assessment of MMP-9 based on den-
sitometric analysis of MMP-9 substrate lysis zones
evidenced a significant reduction (p = 0.0011) between
treated (0.6523 ± 0.3079) and control (0.9893 ± 0.2310)
mice (Figure 2B).Treatment with BB-94 ameliorates intracranial complications
in infected mice
Preliminary observations upon MM model development
indicated that mice infected with N. meningitidis pre-
sented multifocal cortical haemorrhages visible to the
naked eye compared to naïve animals (Ricci, unpublished
data). Therefore, the number and size of cerebral bleed-
ings in BB-94-treated mice were compared to those from
control subjects. Macroscopical examination of brain sam-
ples showed reduced bleeding in animals treated with BB-
94 in comparison with controls (Figure 3A). Quantitative
analysis revealed a 3-fold reduction both in the number of
haemorrhagic spots (Figure 3B; p = 0.0122) and the area of
bleeding (Figure 3C; p = 0.0061) in treated mice. However,
cortical haemorrhages did not translate into large regions
of reduced neuronal density as detectable by Nissl staining
(data not shown).
BB-94 was also beneficial for the integrity of the BBB,
as proven by reduced diffusion of serum albumin in the
brain of treated mice in respect to those injected with
vehicle. Differences between the concentration of albu-
min in BB-94-treated (16,47 ± 10,11 ng/μg total protein)
and control (26,00 ± 13,37 ng/μg) animals were statisti-
cally significant (p = 0.037; Figure 3D).
Evaluation of apoptosis in the dentate gyrus of hippo-
campus showed a trend in the reduction of the apoptosis
score in the treatment group (0,1438 ± 0,1396) compared
to the control one (0,1898 ± 0,1217; p > 0.05).
MMP-9 contributes to brain damage associated with MM
To evaluate whether levels of MMP-9 are associated
with intracranial complications resulting from MM,
Pearson correlation analysis was performed on data
from both control and BB-94-treated mice (Figure 4
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Figure 2 Zymography on cerebella of control and BB-94-treated mice infected with meningococci. Mice were infected and treated as
described in Figure 1. Animals were perfused with cold PBS, and cerebella were harvested and homogenised. As samples were not collected
from dead or unsuccessfully perfused animals, a total of 20 treated mice and 13 control were analysed. Gelatinases in cerebella were enriched by
incubation with gelatin-sepharose and subjected to gelatin zymography. A. Densitometry of gelatinolytic activity around 92 kDa and 72 kDa. Lane 1:
human MMP-9; lane 2: human MMP-2; lanes 3-5: BB-94-treated mice; lanes 6-7: controls. B. Quantification of MMP-9 gelatinolytic activity. Results are
combined from 3 independent experiments. AU, arbitrary units. **p < 0.01.
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mals, the amounts of MMP-9 significantly correlated
with the extent of BBB disruption (ρ = 0.59, p = 0.031;
Figure 4C). Correlation between MMP-9 levels and the
number of haemorrhagic spots (ρ = 0.51, p = 0.079) or
the size of bleeding (ρ = 0.54, p = 0.054) also showed a
tendency towards statistical significance (Figure 4A-B).
In contrast, no significant correlation was observed be-
tween amounts of MMP-9 and intracranial complications
in treated mice (Additional file 1: Table S1). Finally, when
data from both control and BB-94-treated animals were
pooled, MMP-9 levels presented a robust correlation with
the number (ρ = 0.46, p = 0.0067; Figure 4D) and area (ρ =
0.47, p = 0.0049; Figure 4E) of cerebral bleeding, and with
the breakdown of BBB (ρ = 0.44, p = 0.0104; Figure 4F).
Discussion
Successful treatment of BM not only requires antibiotics
to eradicate the pathogen but also adjuvant therapeutic
molecules targeting the host immune and inflammatory
responses. Potential targets of adjuvant therapy are cyto-and chemokines, leukocytes, coagulation cascade mole-
cules, oxidants, caspases, and degrading enzymes [35,36].
To this purpose, several therapeutic approaches have been
attempted in animal models of meningitis caused by
Streptococcus pneumoniae and Streptococcus agalactiae,
including the use of nonbacteriolytic antibiotics, antioxi-
dants, antagonists of excitatory amino acids, and also in-
hibitors of transcription factors, MMPs, caspases, or
complement factors [17-21,33,37-41]. In contrast, data on
adjuvant therapy in MM animal models are scant partially
due to limitations of experimental systems mimicking the
human disease.
In this work, we have fine-tuned a recently described
MM model [30] to study brain damage associated with
MM in the mouse. The model is based on i.c. infection
of adult mice with a sub-lethal dose (~LD20) of live men-
ingococci in order to limit a rapid fatal outcome and per-
mit the development of brain damage. Model readouts
included animal survival and clinical signs, cyto-/chemo-
kines profiling, MMP levels, apoptosis, BBB breakdown,
and intracerebral haemorrhages. Compared to some
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Figure 3 Brain damage in control and BB-94-treated mice after meningococcal challenge. Mice were infected and treated as described in
Figure 1. Brains from perfused animals were collected. A-C. Brain hemispheres were cut in 30 μm cryosections and photographed to determine
the number of haemorrhagic spots and the areas of bleeding. Macroscopical assessment of cerebral haemorrhages in animals injected with BB-94
or vehicle (A). Enumeration of bleeding spots (B) and measurement of haemorrhagic areas (C) were carried out on 5 comparable brain sections/
mouse. D. Following bleeding assessment, brain hemispheres were homogenised, and supernatants were subjected to mouse albumin ELISA to
quantify serum albumin in the brain as a marker of BBB breakdown. Data are displayed as ng of albumin per μg of total protein content of the
brain. Data are from 3 independent experiments. *p < 0.05; **p < 0.01.
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treated with antibiotics, which may influence the
course and profile of the inflammatory response. The
availability of a simple and reliable MM mouse model
allowed, for the first time, to provide evidence that
MMP-9 is involved in the pathogenesis of MM-inducedbrain damage and MMP-9 inhibition significantly im-
proves intracranial complications.
Common histopathologic features of PM include brain
oedema, cortical haemorrhages, focal necrotic lesions in
cortical/subcortical structures and neuronal apoptosis in
the hippocampus [6,7]. PM animal models have largely
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Figure 4 Correlation between MMP-9 levels and intracranial complications in mice with MM. Brain samples from control and treated
animals were subjected to different assays as described in Figures 2 and 3. A-C. Control mice (open squares). D-F. Pooled data of control (open
squares) and BB-94-treated animals (closed squares). The amount of MMP-9 assessed by zymography was associated with the number of bleeding
spots (A, D), the size of haemorrhages (B, E), and the disruption of BBB (C, F). Correlation analysis was performed by the Pearson’s test (p < 0.05).
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damage, including PMN extravasation, neuronal damage
and BBB opening [14-16]. Concerning MM models,
challenge of rats with heat-killed meningococci increased
the levels of MMP-9 mRNA expression and proteolytic ac-
tivity [22] and contributed to BBB disruption [11]. A re-
cent study demonstrated that infection of human brain
microvascular endothelial cells with N. meningitidis in-
duced both the detachment of brain endothelial cells from
the matrix and the cleavage of the tight junction protein
occludin; interestingly, both processes were mediated by
MMP-8, thereby proposing a molecular mechanism be-
hind BBB breakdown during MM [42]. However, these
studies were carried out either in vivo with inactivated
bacteria [11,22] or in vitro [42]. Our work, instead,
employed live meningococci in mice and provided
in vivo evidence that MMP-9 levels significantly corre-
lated with BBB breakdown and cerebral bleeding.
The blood vessel is a major target of both pathogen-
and host-mediated injury in MD. During haematogenous
spread, N. meningitidis interacts with the endothelial
cells of blood vessels throughout the body, including
brain (in MM) and skin (in sepsis). Recently, the skin le-
sions typical of purpura fulminans were reproduced inan experimental model of meningococcemia [43], dem-
onstrating how ‘vascular colonisation’ by meningococci
initiates the thrombotic process [44] that ultimately
leads to vasculitis and vascular rupture. A similar mech-
anism may occur in the blood vessels of the brain during
experimental MM, resulting in cerebral bleeding. On the
host side, MMPs also contribute to the dysfunction of
brain vasculature by disrupting endothelial cell junctions
[42] and promoting BBB opening [11]. MMPs participate
in cerebral haemorrhage of diverse origins [45], and
blocking MMPs is an effective strategy to control brain
(vasogenic) oedema and bleeding size in animal models
of intracerebral haemorrhage [46-49]. In our case, the
correlation between MMP-9 levels and bleeding is con-
sistent with a key role of MMPs in brain haemorrhage,
suggesting that both meningococci and MMPs may have
contributed to intracerebral bleeding in the model.
Inhibitors of MMPs have shown beneficial effects in
experimental studies of neuroinflammatory and neuro-
degenerative conditions, including multiple sclerosis, is-
chaemic and haemorragic stroke, vascular dementia and
meningitis [9,10]. In an infant rat PM model, several
molecules with different inhibitory profiles (MMPs or
TNF-α converting enzyme (TACE)) were able to reduce
Ricci et al. BMC Infectious Diseases  (2014) 14:726 Page 8 of 10animal mortality [19,21], cortical necrosis [15,17-19,21],
hippocampal apoptosis [17,21], BBB disruption [19],
cyto-/chemokine release [21], and also post-infection se-
quelae [17-19]. Batimastat (BB-94) is a hydroxamate
peptidomimetic broad-spectrum MMP inhibitor, but in-
active against TACE. Screening of a wide range of differ-
ent MMP inhibitors in a lipopolysaccharide (LPS)-based
rodent model showed that BB-94 was the most effective
compound at reducing BBB breakdown in both rats and
mice [50]. BB-94 was also useful to diminish BBB dis-
ruption and intracranial pressure in rats infected with
heat-killed N. meningitidis [11]. Moreover, BB-94 signifi-
cantly reduced the incidence of haemorrhage associated
with administration of thrombolytic drugs in rabbits suf-
fering from stroke, demonstrating the added value of
BB-94 in controlling experimental brain bleeding [46].
In this study, treatment with BB-94 increased mouse
survival and alleviated the severity of intracranial compli-
cations. Kaplan-Meier survival curves showed a tendency
towards a significant difference between treated and con-
trol animals. The lack of statistical significance may be
due to the relatively small sample size of animal groups af-
fecting statistical power. In contrast, brain damage was
significantly reduced in BB-94-treated subjects compared
to controls. To emphasise this result, it is worth noticing
that mice (of which 87.5% were controls) that died before
the experimental endpoint at 48 h were not assessed for
brain injury, thereby potentially excluding the most acute
cases from the analyses. BB-94 may have operated via dif-
ferent mechanisms, including: (i) a direct effect on the
brain microvasculature by limiting vascular rupture and
BBB breakdown, or (ii) an indirect action on the systemic
inflammatory response by reducing MMP-dependent acti-
vation of pro-inflammatory mediators. However, the fact
that levels of brain cyto- and chemokines were not signifi-
cantly reduced in treated mice argues for a direct vasculo-
protective effect by BB-94. In BB-94 treated mice, MMP-9
levels did not significantly correlate with intracerebral
complications, suggesting that other factors than MMP-9
may be responsible for the residual brain damage detect-
able in treated animals.
Drugs that block MMPs are considered a double-edged
sword in clinical practice. On one hand, they represent a
therapeutic asset in neuroinflammation, while on the
other, they may wedge crucial recovery functions, such as
neurovascular remodelling and neurogenesis [10]. Never-
theless, MM is an acute condition for which a short-term
adjuvant therapy with MMP inhibitors may be envisioned
to protect the neurovascular unit.
Conclusions
This study describes the development of a novel murine
model of MM-induced brain damage that allows the
assessment of different clinical, histopathological andimmunological parameters. The model may be valuable
in the MM/MD field where experimental systems mim-
icking the human disease are lacking. The use of such
in vivo model enabled us to demonstrate that: (i) MMP-
9 contributes to neuronal injury in MM, and (ii) MMP-9
inhibition improves disease outcome, indicating that
MMP-9 may represent an important target for adjuvant
therapy in MM. The present data are consistent with the
literature highlighting the role of MMPs in PM, thus
suggesting MMPs as universal mediators of brain dam-
age in acute BM irrespective of the causative agent. Fu-
ture studies will investigate the efficacy of MMP
inhibitors as adjuvant therapy in combination with anti-
biotics in experimental MM.
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